Literature DB >> 19752400

Polyclonality of BRAF mutations in acquired melanocytic nevi.

Jingrong Lin1, Minoru Takata, Hiroshi Murata, Yasufumi Goto, Kenji Kido, Soldano Ferrone, Toshiaki Saida.   

Abstract

Melanocytic nevi are thought to be senescent clones of melanocytes that have acquired an oncogenic BRAF mutation. BRAF mutation is considered to be a crucial step in the initiation of melanocyte transformation. However, using immunomagnetic separation or laser-capture microdissection, we examined BRAF mutations in sets of approximately 50 single cells isolated from acquired melanocytic nevi from 13 patients and found a substantial number of nevus cells that contained wild-type BRAF mixed with nevus cells that contained BRAF(V600E). Furthermore, we simultaneously amplified BRAF exon 15 and a neighboring single nucleotide polymorphism (SNP), rs7801086, from nevus cell samples obtained from four patients who were heterozygous for this SNP. Subcloning and sequencing of the polymerase chain reaction products showed that both SNP alleles harbored the BRAF(V600E) mutation, indicating that the same BRAF(V600E) mutation originated from different cells. The polyclonality of BRAF mutations in acquired melanocytic nevi suggests that mutation of BRAF may not be an initial event in melanocyte transformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752400      PMCID: PMC2765260          DOI: 10.1093/jnci/djp309

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Detailed investigation of factors influencing amplification efficiency and allele drop-out in single cell PCR: implications for preimplantation genetic diagnosis.

Authors:  Wirawit Piyamongkol; Mercedes G Bermúdez; Joyce C Harper; Dagan Wells
Journal:  Mol Hum Reprod       Date:  2003-07       Impact factor: 4.025

2.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

3.  Naming acquired melanocytic nevi. Unna's, Miescher's, Spitz's Clark's.

Authors:  A B Ackerman; M Magana-Garcia
Journal:  Am J Dermatopathol       Date:  1990-04       Impact factor: 1.533

4.  Cyto-genotoxic species leakage within human melanoma melanosomes. Molecular-morphological correlations.

Authors:  M Miranda; F Amicarelli; A Poma; A M Ragnelli; C Scirri; P P Aimola; L Masciocco; A Bonfigli; O Zarivi
Journal:  Biochem Mol Biol Int       Date:  1994-04

Review 5.  Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.

Authors:  Michael R Campoli; Chien-Chung Chang; Toshiro Kageshita; Xinhui Wang; James B McCarthy; Soldano Ferrone
Journal:  Crit Rev Immunol       Date:  2004       Impact factor: 2.214

6.  X-inactivation patch size in human female tissue confounds the assessment of tumor clonality.

Authors:  Marco Novelli; Antonio Cossu; Dahmane Oukrif; Alberto Quaglia; Sunil Lakhani; Richard Poulsom; Peter Sasieni; Piera Carta; Marcella Contini; Anna Pasca; Giuseppe Palmieri; Walter Bodmer; Francesco Tanda; Nick Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-27       Impact factor: 11.205

7.  BRAFE600-associated senescence-like cell cycle arrest of human naevi.

Authors:  Chrysiis Michaloglou; Liesbeth C W Vredeveld; Maria S Soengas; Christophe Denoyelle; Thomas Kuilman; Chantal M A M van der Horst; Donné M Majoor; Jerry W Shay; Wolter J Mooi; Daniel S Peeper
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

9.  Human acquired naevi are clonal.

Authors:  W A Robinson; M Lemon; A Elefanty; M Harrison-Smith; N Markham; D Norris
Journal:  Melanoma Res       Date:  1998-12       Impact factor: 3.599

10.  Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors.

Authors:  Yasufumi Goto; Takaaki Arigami; Minoru Kitago; Sandy L Nguyen; Norihiko Narita; Soldano Ferrone; Donald L Morton; Reiko F Irie; Dave S B Hoon
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

View more
  22 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms.

Authors:  Joel Pinczewski; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2010-10       Impact factor: 3.960

3.  Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation.

Authors:  Joseph B Hiatt; Colin C Pritchard; Stephen J Salipante; Brian J O'Roak; Jay Shendure
Journal:  Genome Res       Date:  2013-02-04       Impact factor: 9.043

4.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

Review 5.  Biological challenges of BRAF inhibitor therapy.

Authors:  Igor Puzanov; Patrick Burnett; Keith T Flaherty
Journal:  Mol Oncol       Date:  2011-02-16       Impact factor: 6.603

Review 6.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

Review 7.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

Review 8.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

Review 9.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

10.  Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.

Authors:  Iwei Yeh; Andreas von Deimling; Boris C Bastian
Journal:  J Natl Cancer Inst       Date:  2013-05-20       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.